Regeneron and Sanofi to Present New Analyses from the Praluent® (alirocumab) Injection ODYSSEY Clinical Trial Program at the AHA Scientific Sessions 2017
Go back to Regeneron and Sanofi to Present New Analyses from the Praluent® (alirocumab) Injection ODYSSEY Clinical Trial Program at the AHA Scientific Sessions 2017| Regeneron (NASDAQ: REGN) | Delayed: 810.31 -17.41 (2.1%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $827.72 | 52 Week High | $592.36 | |||
| Open | $814.36 | 52 Week Low | $325.35 | |||
| Day High | $821.17 | P/E | 212.68 | |||
| Day Low | $799.42 | EPS | $3.81 | |||
| Volume | 556,536 | |||||
